AAAAAA

   
Results: 1-10 |
Results: 10

Authors: Demarquay, D Huchet, M Coulomb, H Lesueur-Ginot, L Lavergne, O Kasprzyk, PG Bailly, C Camara, J Bigg, DCH
Citation: D. Demarquay et al., The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison, ANTI-CANC D, 12(1), 2001, pp. 9-19

Authors: Lansiaux, A Facompre, M Wattez, N Hildebrand, MP Bal, C Demarquay, D Lavergne, O Bigg, DCH Bailly, C
Citation: A. Lansiaux et al., Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60cells, MOLEC PHARM, 60(3), 2001, pp. 450-461

Authors: Larsen, AK Gilbert, C Chyzak, G Plisov, SY Naguibneva, I Lavergne, O Lesueur-Ginot, L Bigg, DCH
Citation: Ak. Larsen et al., Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells, CANCER RES, 61(7), 2001, pp. 2961-2967

Authors: Philippart, P Harper, L Chaboteaux, C Decaestecker, C Bronckart, K Gordover, L Lesueur-Ginot, L Malonne, H Lavergne, O Bigg, DCH da Costa, PM Kiss, R
Citation: P. Philippart et al., Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human coloncancers obtained from surgery and maintained in vitro under histotypical culture conditions, CLIN CANC R, 6(4), 2000, pp. 1557-1562

Authors: Lavergne, O Demarquay, D Bailly, C Lanco, C Rolland, A Huchet, M Coulomb, H Muller, N Baroggi, N Camara, J Le Breton, C Manginot, E Cazaux, JB Bigg, DCH
Citation: O. Lavergne et al., Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins, J MED CHEM, 43(11), 2000, pp. 2285-2289

Authors: Lavergne, O Harnett, J Rolland, A Lanco, C Lesueur-Ginot, L Demarquay, D Huchet, M Coulomb, H Bigg, DCH
Citation: O. Lavergne et al., BN 80927: A novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II, BIOORG MED, 9(17), 1999, pp. 2599-2602

Authors: Lesueur-Ginot, L Demarquay, D Kiss, R Kasprzyk, PG Dassonneville, L Bailly, C Camara, J Lavergne, O Bigg, DCH
Citation: L. Lesueur-ginot et al., Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties, CANCER RES, 59(12), 1999, pp. 2939-2943

Authors: Bailly, C Lansiaux, A Dassonneville, L Demarquay, D Coulomb, H Huchet, M Lavergne, O Bigg, DCH
Citation: C. Bailly et al., Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks, BIOCHEM, 38(47), 1999, pp. 15556-15563

Authors: Lavergne, O Lesueur-Ginot, L Rodas, FP Kasprzyk, PG Pommier, J Demarquay, D Prevost, G Ulibarri, G Rolland, A Schiano-Liberatore, AM Harnett, J Pons, D Camara, J Bigg, DCH
Citation: O. Lavergne et al., Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues, J MED CHEM, 41(27), 1998, pp. 5410-5419

Authors: Lavergne, O Bigg, DCH
Citation: O. Lavergne et Dch. Bigg, The other camptothecins: recent advances on camptothecin analogs other than irinotecan and topotecan, B CANCER, 1998, pp. 51-58
Risultati: 1-10 |